Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Biocept, Inc. (Nasdaq: BIOC) will host a webinar on April 8, 2021, featuring leading neuro-oncologists discussing its proprietary cerebrospinal fluid (CSF) assay. This assay aims to improve the diagnosis and management of tumors metastasizing to the central nervous system, showing enhanced sensitivity compared to the current standard, CSF cytology. The company anticipates significant interest and has estimated the market opportunity for brain metastasis diagnostics at over $1 billion annually, addressing a critical unmet clinical need.
- None.
- None.
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss the use of the Company’s proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that have metastasized to the central nervous system (CNS), including the brain or spinal column. Biocept’s CSF assay provides enhanced sensitivity compared with CSF cytology, the current standard of care, and has the added advantage of identifying actionable molecular targets for use in treatment decisions while providing quantitative information needed for assessing treatment response and monitoring disease progression.
“Our goal is to establish our CSF assay as the new standard of care for the diagnosis of patients with suspected cancer metastasis to the CNS under National Comprehensive Cancer Network guidelines,” said Michael Dugan, MD, Biocept’s Senior Vice President, Chief Medical Officer and Medical Director. “We have already gained substantial interest among neuro-oncologists and other cancer specialists from nearly two dozen leading academic institutions across the country. Most of these physicians have already ordered our CSF assay with many becoming repeat users.
“The CSF assay addresses a high unmet clinical need as current diagnostic tools for patients with brain metastases are inadequate or imprecise for assessing therapy response; however, many therapies are now available that offer substantial promise for improved survival and resolution of symptoms,” Dr. Dugan added. “Between
Webinar Details
Date: |
Thursday, April 8, 2021 |
Time: |
12:00 p.m. Eastern time (9:00 a.m. Pacific time) |
Registration: |
Participants can pre-register or register at webinar start time here. |
The webinar also will be available live and archived at https://ir.biocept.com/.
Amir Azadi, MD is a medical oncologist specializing in neuro-oncology and an Assistant Professor in the Department of Neurology at Barrow Neurological Institute. His expertise includes the diagnosis and treatment of brain tumors. He is board certified in internal medicine and medical oncology by the American Board of Internal Medicine, and is a member of the American College of Physicians, the American Society of Clinical Oncology, the Society for Immunotherapy of Cancer and the Society of Neuro-Oncology. Dr. Azadi received his medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran. He completed his residency in internal medicine at Banner – University Medical Center in Phoenix, and fellowships in hematology and oncology at the University of Louisville James Graham Brown Cancer Center and in neuro-oncology at Barrow Neurological Institute.
Nicholas Blondin, MD is Assistant Professor of Clinical Neurology at Yale School of Medicine. His clinical expertise is in treating benign and malignant brain tumors, brain and spine metastasis, and neurological symptoms of cancer such as seizures, cognitive impairment, headaches, gait disturbance and weakness. Dr. Blondin is an active investigator for clinical trials for brain tumor patients through Yale Cancer Center. He received his Medical Degree from the University of Connecticut School of Medicine and completed his neurology residency at Yale New Haven Hospital, where he was Chief Resident in Neurology, followed by a fellowship in neuro-oncology at Yale New Haven Hospital.
Priya U. Kumthekar, MD is a United Counsel for Neurologic Subspecialties (UCNS)-certified neuro-oncologist from Northwestern University and is serving as the principal investigator for Biocept’s Four C clinical study. She is dedicated to patient care and moving the study of brain tumors forward primarily through her leadership on clinical trials. Dr. Kumthekar serves in leadership roles with the National Clinical Trials Network, particularly with the Alliance for Clinical Trials, and was named as the Alliance’s national Executive Officer of Neuro-Oncology in 2016. In this role, she oversees the conception and development of clinical trials from early phase through registration studies. Dr. Kumthekar is board certified in neurology and is a member of the American Board of Psychiatry and Neurology. She received her medical degree from Northeastern Ohio University. She previously was Chief Resident at Northwestern University, McGaw Medical Center.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept is developing and commercializing its cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system. The Company’s CSF assay identifies molecular targets for clinical decision making and provides quantitative information for monitoring treatment response. Biocept’s patented Target Selector™ technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) with higher sensitivity and specificity than most commercial assays. Additionally, Biocept is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For additional information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to establish our CSF assay as the new standard of care for the diagnosis of patients with suspected cancer metastasis to the CNS under National Comprehensive Cancer Network guidelines and our ability to provide physicians with clinically actionable information to improve the outcomes of cancer patients, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at http://www.sec.gov/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005271/en/
FAQ
What is the purpose of Biocept's upcoming webinar on April 8, 2021?
What time does Biocept's webinar on April 8, 2021, start?
How does Biocept's CSF assay compare to the current standard of care?
What market opportunity does Biocept estimate for brain metastasis diagnostics?
How can participants register for Biocept's webinar on April 8, 2021?
